Treatment of BCC cells with various AP-1 small-molecule inhibitors (T522434 and SR1130235) resulted in a dose-dependent decrease in expression of Gli1 measured by mRNA and protein, and cell viability (Fig. 3d, e and Supplementary Fig. 3b, c). This evidence concerns the gene JUN and skin basal cell carcinoma.